Details of the Drug

General Information of Drug (ID: DMUAXS5)

Drug Name
FP-1039
Synonyms
FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences
Indication
Disease Entry ICD 11 Status REF
Endometrial cancer 2C76 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1b [2]
Cross-matching ID
TTD ID
D0U2DO
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor 1 (FGFR1) TTRLW2X FGFR1_HUMAN Antagonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Endometrial cancer
ICD Disease Classification 2C76
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fibroblast growth factor receptor 1 (FGFR1) DTT FGFR1 4.79E-02 -0.03 -0.15
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01244438) Study of FP-1039 in Subjects With Endometrial Cancers. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Five Prime Therapeutics.
3 FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine. 2012; 7: 5915-5927.